Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Chinese Academy of Medical Sciences · 2021
ClinicalTrials.gov · Datasets · License: Public Domain · 2021
Open Source ↗
relapse
dlbcl, myd88 gene mutation, cd79a gene mutation, cd79b gene mutation, relapse, refractory lymphoma, r/r dlbcl, cd79a/b gene mutation, ibrutinib, rituximab, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 910790
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.